Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double‐blind, parallel‐group study

@article{Kuna2009EfficacyAS,
  title={Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double‐blind, parallel‐group study},
  author={Piotr Kuna and Claus Bachert and Zygmunt Nowacki and Paul Van cauwenberge and Ioana Agache and L Fouquert and Albert Roger and Ander Sologuren and Rom{\'a}n Valiente},
  journal={Clinical \& Experimental Allergy},
  year={2009},
  volume={39}
}
BACKGROUND Bilastine is a new non-sedative H(1) receptor antagonist, indicated for the treatment of allergic rhinitis (AR) (seasonal and perennial. [] Key MethodMETHODS Overall, 683 SAR patients, aged 12-70 years, were randomized to a double-blind treatment with bilastine 20 mg, cetirizine 10 mg or placebo, once daily for 14 days, in 61 centres across Europe.

Original article Efficacy and safety of bilastine 20mg compared with cetirizine 10mg and placebo in the treatment of perennial allergic rhinitis

Bilastine is a non-sedating second-generation H1 antihistamine with proven efficacy and safety in the treatment of patients with seasonal allergic rhinitis and urticaria and is demonstrated to be effective and safe in patients with perennial allergicrhinitis.

Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi‐centre, double‐blind, randomized, placebo‐controlled study

To cite this article: Zuberbier T, Oanta A, Bogacka E, Medina I, Wesel F, Uhl P, Antépara I, Jáuregui I, Valiente R, the Bilastine International Working Group. Comparison of the efficacy and safety

Bilastine: a guide to its use in the treatment of symptomatic allergic rhinoconjunctivitis and urticaria

Bilastine is a new antihistamine indicated for the symptomatic treatment of seasonal or perennial allergic rhinoconjunctivitis and urticaria, with an overall tolerability profile similar to that of placebo.

Quality of life in patients with allergic rhinitis: a clinical trial comparing the use of bilastine versus loratadine

  • R.B. LocksK. SantosJ. Silva
  • Medicine, Psychology
    Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery
  • 2017
The aim of this study was to determine whether there were differences in health‐related quality of life of patients with allergic rhinitis treated with bilastine 20 mg compared to those treated with

Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis

A post-hoc analysis indicated that bilastine and cetirizine were similarly effective and more effective than placebo during a 4-week treatment period in patients with PAR and was shown to be safe and well-tolerated over a 1-year treatment period.

Safety and tolerability of bilastine 10 mg administered for 12 weeks in children with allergic diseases

The safety and tolerability of bilastine 10 mg in children with allergic rhinoconjunctivitis and chronic urticaria is assessed.

Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria : a multi-centre , double-blind , random-ized , placebo-controlled study

Department of Dermatology and Allergy, Charité Universitätsmedizin Berlin, Germany; S. C. Dermamed SRL, Brasov, Romania; NZOZ Materia Medica, Wroclaw, Poland; Centro Médico Vitae, Buenos Aires,

[Pollinosis: drug treatments].

  • R. Harf
  • Medicine
    Revue des maladies respiratoires
  • 2013

Ef fi cacy and safety of bilastine in Japanese patients with perennial allergic rhinitis : A multicenter , randomized , double-blind , placebo-controlled , parallel-group phase III study

After 2-week treatment period, bilastine 20 mg once daily was effective and tolerable in Japanese patients with PAR, and exhibited a rapid onset of action.
...

References

SHOWING 1-10 OF 29 REFERENCES

Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients

The objective of this study was to compare the efficacy and safety of bilastine 20 mg vs placebo and desloratadine 5’mg in subjects with seasonal allergic rhinitis (SAR).

Oral antihistamines for the symptom of nasal obstruction in persistent allergic rhinitis – a systematic review of randomized controlled trials

Background Oral antihistamines are recommended by a World Health Organisation working group as a first‐line pharmacological treatment in mild persistent allergic rhinitis. There is, however,

The health‐related quality of life effects of once‐daily cetirizine HCl in patients with seasonal allergic rhinitis: a randomized double‐blind, placebo‐controlled trial

  • M. NoonanG. Raphael B. Kramer
  • Medicine, Psychology
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
  • 2003
The objective of this study was to test the effect of cetirizine HCl 10 mg once daily on the HRQL of adult patients 18–65 years of age with SAR, concurrently assessing safety and efficacy.

Advances in H1-antihistamines.

  • F. Simons
  • Medicine, Biology
    The New England journal of medicine
  • 2004
There are clinically relevant differences among H1-antihistamines in their pharmacology and safety profiles in allergic rhinoconjunctivitis and chronic urticaria.

Validation of the classification of ARIA (allergic rhinitis and its impact on asthma)

The recent Allergic Rhinitis and its Impact on Asthma (ARIA) workshop proposes to replace these terms by intermittent vs persistent rhinitis.

Comprehensive evaluation of cetirizine in the management of seasonal allergic rhinitis: impact on symptoms, quality of life, productivity, and activity impairment.

Cetirizine provides safe and effective symptomatic relief in adults with SAR while significantly improving HRQL and providing a positive impact on work/school-related productivity and activity impairment.

Comparison of Peripheral and Central Effects of Single and Repeated Oral Dose Administrations of Bilastine, a New H1 Antihistamine: A Dose-Range Study in Healthy Volunteers With Hydroxyzine and Placebo as Control Treatments

A clear dissociation between peripheral anti-H1 and central nervous system activity was found after BIL treatment and significant and sustained peripheral H1-blocking effects were observed after both single and repeated administrations of the therapeutic dose of 20 mg BIL.

A treatment for allergic rhinitis:a view on the role of levocetirizine

Both the short-term and long-term use of levocetirizine in the clinical management of allergic rhinitis is supported, with an increased benefit over other antihistamines in terms of a more durable antihistamine response.

Economic impact and quality-of-life burden of allergic rhinitis

It was concluded that greater awareness of the total economic burden of allergic rhinitis should encourage appropriate intervention and ultimately ensure clinically favorable and cost-effective outcomes.

Consensus group on new‐generation antihistamines (CONGA): present status and recommendations

  • S. HolgateG. Canonica K. Yanai
  • Medicine
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
  • 2003
This paper presents a meta-analysis of published work and concludes that further studies are needed to assess the appropriateness of the current treatment of smoking cessation practices in relation to alcohol and drug abuse.